Objective:

To analyze the scrutiny and guidelines surrounding the use of modifier -25 for same-day office visits with intravitreal injections, highlighting the implications of improper use.

Key Findings:

• 42% of intravitreal injections were billed with modifier -25, raising concerns about compliance.
• The OIG recommended updates to Medicare requirements and additional education on modifier -25 to prevent improper billing.
• Modifier -25 should not be used based solely on a new diagnosis or new patient status; documentation must support a distinct service.

Interpretation:

The scrutiny from OIG, SMRC, and CMS indicates a strong focus on reducing improper payments related to modifier -25, necessitating clear documentation for claims to avoid penalties.

Limitations:

• The audit reviewed a limited number of claims (24) across 12 jurisdictions.
• The findings may not represent all practices or regions.

Conclusion:

Practices should enhance internal reviews and documentation standards, including specific training for staff, to ensure compliance with modifier -25 requirements.